The effect of newly somatostatin analogues for neuroendocrine tumor

The effect of newly somatostatin analogues for neuroendocrine tumor - Medication for nueroendocrine tumor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028537

Enrollment

Registered

2017-08-31

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuroendocrine tumor

Interventions

pasireotide, 60mg/4weeks, 12 mo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who have endocrine tumor enlargement after administration of octreitide LAR.

Exclusion criteria

Exclusion criteria: non

Design outcomes

Primary

Measure	Time frame
To evaluate tumor shrinkage and hormon secretion from tumor after administration of newly somatostatin analogues.	—

Countries

Japan

Contacts

Public ContactItsuro ENDO

Tokushima University Hospital Endocrinology and Metabolism

endoits@tokushima-u.ac.jp088-633-7120

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026